BridgeMD
Study of HM15912 in subjects with Short Bowel Syndrome-associated Intestinal Failure
EU CTIS ID: 2024-515160-32-00
What this study is testing
1) To assess safety and tolerability of HM15912 after multiple subcutaneous (SC) doses for 24 weeks 2) To assess the pharmacokinetic (PK) profile of HM15912
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Men or women aged 18 years or older with confirmed diagnosis of SBS.
- Had their most recent bowel surgery at least 6 months before joining the study.
- Subjects must either have no growth of cancer cells in their large intestine or have had any growths removed during a bowel examination within 6 months before joining the study.
- Subjects must have an opening on their abdomen, commonly called stoma, created by an operation that connects their small intestine to the outside of their body.
You likely can't join if
- History of colon cancer, or any other current or prior medical conditions that would make it difficult to participate in the study.
- History of alcohol or drug abuse
- Have a body weight >100 kg and repeated blood pressure measurements > 140 mm Hg.
The study team makes the final eligibility decision.
Where it's taking place
- Korea, Republic of
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Korea, Republic of; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.